• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by FSD Pharma Inc. (Amendment)

    4/11/22 10:01:53 AM ET
    $HUGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HUGE alert in real time by email
    SC 13D/A 1 d327739dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    FSD Pharma, Inc.

    (Name of Issuer)

    Class B Subordinate Voting Shares, no par value per share

    (Title of Class of Securities)

    35954B206

    (CUSIP Number)

    Dr. Raza Bokhari

    437 North Spring Mill Road

    Villanova, PA 19085

    610-329-3839

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    January 14, 2022

    (Date of Event Which Requires Filing of This Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     

     


    CUSIP No. 35954B206

     

      (1)    

       Names of Reporting Persons

     

      Dr. Raza Bokhari

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      (3)  

      SEC Use Only

     

      (4)  

      Source of Funds (See Instructions)

     

      PF

      (5)  

      Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      (6)  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

         (7)    

      Sole Voting Power

     

      418,483(1)

         (8)  

      Shared Voting Power

     

      0

         (9)  

      Sole Dispositive Power

     

      418,483(1)

       (10)  

      Shared Dispositive Power

     

    (11)    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      418,483(1)

    (12)  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11)

     

      1.09% (2)

    (14)  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (1)

    Includes 412,932 Class B Shares underlying stock options (the “Options”) that the Reporting Person has the right to acquire within 60 days of the date hereof (the “Option Shares”) and 24 Class B Shares issuable to the Reporting Person upon conversion of 24 Class A Multiple Voting Shares, no par value, of the Issuer (“Class A Shares”) held by the Reporting Person that the Reporting Person has the right to acquire within 60 days of the date hereof (the “Class A Converted Shares”). Each Class A Share is convertible at any time into one Class B Share.

    (2)

    Based on 38,491,345 Class B Shares outstanding as of March 30, 2022, as reported in the Issuer’s Form 20-F dated as of March 30, 2022, and an additional 412,932 Option Shares and 24 Class A Converted Shares. Each Class A Share is treated as converted into one Class B Share for purposes of computing the percentage ownership of the Reporting Person. Each Class A Share is entitled to 276,660 votes, and each Class B Share is entitled to one vote. The percentage reported does not reflect the 276,660-for-one voting power of the Class A shares.

     

    2


    Explanatory Note

    This Amendment No. 2 to Schedule 13D (“Amendment No. 2”) is being filed by Raza Bokhari, M.D. (the “Reporting Person”), pursuant to Rule 13d-2(a) under the Exchange Act, to amend the Schedule 13D filed on September 8, 2020, as amended on February 17, 2021 (the “Schedule 13D”) relating to Class B Subordinate Voting Shares, no par value per share (the “Class B Shares”), of FSD Pharma, Inc., an Ontario corporation (the “Issuer”). Except as set forth below, all Items of the Schedule 13D remain unchanged.

    Item 2. Identity and Background.

    Item 2 is hereby restated in its entirety as follows.

    (a) This statement is filed by Raza Bokhari, M.D.

    (b) The business address of the Reporting Person is 437 North Spring Mill Road, Villanova, PA 19085.

    (c) The principal occupation of the Reporting Person is Chairman of Parkway Clinical Laboratories, Inc.

    (d) & (e) During the last five years, the Reporting Person (i) has not been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) and (ii) has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    (f) The Reporting Person is a citizen of the United States of America.

    Item 3. Source and Amount of Funds or Other Consideration.

    Item 3 is hereby supplemented as follows:

    On January 14, 2022, Dr. Bokhari sold 31,583 Class B Shares through the facilities of the Canadian Securities Exchange (the “CSE”) for approximately CAD$1.28 per Class B Share for gross proceeds of approximately CAD$40,370.34.

    Between January 17, 2022 and March 25, 2022, Dr. Bokhari sold 1,883,820 Class B Shares through the facility of the CSE at a weighted average sale price of approximately CAD$1.09 per Class B Shares for gross proceeds of approximately CAD$2,058,136.32.

    On March 29, 2022, the Issuer cancelled, for nil consideration, 504,888 Class B Shares that were originally issued to Dr. Bokhari on February 10, 2021.


    Item 4. Purpose of Transaction.

    Item 4 is hereby supplemented as follows:

    In 2022, Dr. Bokhari disposed of Class B Shares in order to monetize a portion of his interest in the Issuer. Dr. Bokhari holds securities of the Issuer for investment purposes and has no present intention to acquire or dispose of such securities. Depending on various factors, including, without limitation, market conditions, general economic and industry conditions, the Issuer’s business and financial condition and/or any other factors that Dr. Bokhari may deem relevant, Dr. Bokhari may, in the future and subject to applicable law, acquire or dispose of Class A Shares, Class B Shares or other securities of the Issuer.

    Item 5. Interest in Securities of the Issuer.

    Item 5 is hereby amended and restated in its entirety as follows.

    (a)-(b) See Items 7-11 of the cover page and Item 2 above.

    (c) Except as set forth below, there have been no reportable transactions with respect to the Class B Shares by the Reporting Person during the past 60 days.

     

    Date of Sale

       Shares Sold      Average Price
    Per Share
    (CAD$):
     

    1/14/2022

         31,583      $ 1.28  

    1/17/2022

         25,647      $ 1.31  

    1/18/2022

         48,500      $ 1.30  

    1/19/2022

         6,500      $ 1.29  

    1/20/2022

         53,253      $ 1.27  

    1/21/2022

         67,500      $ 1.25  

    1/24/2022

         104,600      $ 1.09  

    1/25/2022

         67,000      $ 1.08  

    1/26/2022

         29,100      $ 1.14  

    1/27/2022

         38,000      $ 1.13  

    1/28/2022

         79,900      $ 1.07  

    1/31/2022

         20,400      $ 1.09  

    2/1/2022

         50,900      $ 1.08  

    2/2/2022

         25,500      $ 1.07  

    2/3/2022

         55,000      $ 1.03  

    2/4/2022

         43,500      $ 1.06  

    2/7/2022

         90,000      $ 1.05  

    2/8/2022

         46,800      $ 1.06  

    2/9/2022

         84,000      $ 1.07  

    2/10/2022

         70,000      $ 1.10  

    2/11/2022

         34,300      $ 1.08  

    2/14/2022

         35,200      $ 1.05  

    2/15/2022

         30,800      $ 1.06  

    2/16/2022

         65,000      $ 1.07  

    2/17/2022

         43,600      $ 1.05  

    3/16/2022

         42,800      $ 1.06  

    3/17/2022

         50,020      $ 1.03  

    3/18/2022

         88,000      $ 1.05  

    3/21/2022

         56,000      $ 1.05  

    3/22/2022

         54,600      $ 1.03  

    3/23/2022

         73,000      $ 1.05  

    3/24/2022

         104,600      $ 1.05  

    3/25/2022

         199,800      $ 1.11  


    The above listed transactions were conducted in the ordinary course of business on the open market for cash.

    (d) Except as otherwise described herein, and to the knowledge of the Reporting Person, no person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from sale of, the securities of the Issuer reported herein.

    (e) Not applicable.


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: April 11, 2022     Raza Bokhari, M.D.
        By:  

    /s/ Raza Bokhari

    Get the next $HUGE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HUGE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HUGE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for Ontario

      TORONTO, April 14, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announced that the reconsideration motion by Dr. Raza Bokhari at the Court of Appeal for Ontario was dismissed entirely in favour of Quantum BioPharma. Dr. Raza Bokhari, current CEO of Medicus Pharma, Ltd., was CEO of FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) now Qu

      4/14/25 7:30:00 AM ET
      $HUGE
      $QNTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Quantum Biopharma in Court With Dr. Raza Bokhari on January 24, 2025 Seeking a Court Order to Declare Him to Be a Vexatious Litigant and Other Litigation Updates

      Awards in favour of Quantum BioPharma Total Approximately $3 Million TORONTO, ON / ACCESS Newswire / January 17, 2025 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announced that it will be back in the Ontario Superior Court of Justice on January 24, 2025. Quantum BioPharma is seeking a Court Order declaring Dr. Raza Bokhari, current CEO of Medicus Pharma,

      1/17/25 7:30:00 AM ET
      $HUGE
      $QNTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Quantum BioPharma Previously Known as FSD Pharma (Nasdaq:HUGE) (CSE:HUGE) Invites Shareholders to Come Forward and Join Hands With the Company in the US700M$+ Court Case the Company Has Filed Against CIBC, RBC, and Others for Alleged Spoofing/Stock Price Manipulation

      TORONTO, ON / ACCESSWIRE / November 25, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) (the "Company") formerly named FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE) is pleased to follow up on recent events concerning the complaint filed by the Company in the United States courts, that alleges that CIBC World Markets, RBC Dominion Securities and others (the "Defendants") engaged in market manipulation in the share price of the Company. The Company, as well as its shareholders, have suffered financial and emotional losses resulting from this alleged manipulation. We are determined to right this wrong by the Defendants and reverse the Company losses and claim punitive damages to the e

      11/25/24 7:00:00 AM ET
      $HUGE
      $QNTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HUGE
    Leadership Updates

    Live Leadership Updates

    See more
    • Quantum BioPharma Previously Known as FSD Pharma (Nasdaq:HUGE) (CSE:HUGE) Invites Shareholders to Come Forward and Join Hands With the Company in the US700M$+ Court Case the Company Has Filed Against CIBC, RBC, and Others for Alleged Spoofing/Stock Price Manipulation

      TORONTO, ON / ACCESSWIRE / November 25, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) (the "Company") formerly named FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE) is pleased to follow up on recent events concerning the complaint filed by the Company in the United States courts, that alleges that CIBC World Markets, RBC Dominion Securities and others (the "Defendants") engaged in market manipulation in the share price of the Company. The Company, as well as its shareholders, have suffered financial and emotional losses resulting from this alleged manipulation. We are determined to right this wrong by the Defendants and reverse the Company losses and claim punitive damages to the e

      11/25/24 7:00:00 AM ET
      $HUGE
      $QNTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FSD Pharma Announces Dr. Sanjiv Chopra is elected to FSD Pharma Board of Directors and Corporate Updates

      TORONTO, ON / ACCESSWIRE / January 29, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions is pleased to announce the appointment of Dr. Sanjiv Chopra to its board of directors. Dr. Chopra will be replacing Nitin Kaushal, who has resigned from his position on the board. FSD Pharma thanks Mr. Kaushal for his contribution and wishes him well on his future endeavours.Dr. Sanjiv ChopraDr. Sanjiv Chopra, MD, is Professor of Medicine and served as Faculty Dean for Continuing Medical Education at Harvard Medical School for 12 years. He serves as a Marshall W

      1/29/24 4:30:00 PM ET
      $HUGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FSD Pharma Files Supplement to Management Information Circular in Connection with Special Meeting to be Held on November 20, 2023

      TORONTO, ON / ACCESSWIRE / November 15, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions,is pleased to announce that it has provided certain additional disclosure, by way of a Supplement dated November 15, 2023 (the "Supplement") to its Management Information Circular dated October 20, 2023 (the "Circular"), relating to certain restrictions on resale that will apply to the Celly Nu Shares that will be distributed to the FSD Pharma Securityholders. Capitalized terms not defined in this news release have the meanings assigned in the Circular.FSD Phar

      11/15/23 9:00:00 AM ET
      $HUGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HUGE
    Financials

    Live finance-specific insights

    See more
    • Goldman Small Cap Research Publishes New Research Report on FSD Pharma, Inc.

      BALTIMORE, MD / ACCESSWIRE / November 24, 2023 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on FSD Pharma, Inc. (NASDAQ:HUGE)(CSE:HUGE), an innovative biopharmaceutical firm with one product slated for commercialization in 1Q24 and a unique treatment for MS preparing a Phase II clinical trial for 2H24 The Goldman report carries a price target. To view the new research report, along with disclosures and disclaimers, or to download the report in its entirety, please visit https://bit.ly/3Rer5Av.FSD Pharma is a biopharmaceutical company building a portfolio of innovative

      11/24/23 7:55:00 AM ET
      $HUGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FSD Pharma Inc. Securityholders Approve Plan of Arrangement with Celly Nutrition Corp.

      TORONTO, ON / ACCESSWIRE / November 21, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that the FSD Pharma Securityholders (defined below) have approved the previously-announced plan of arrangement under section 182 of the Business Corporations Act (Ontario) (the "Arrangement") pursuant to which common shares in the capital of Celly Nutrition Corp. ("Celly Nu"), will be distributed to the holders of class A multiple voting shares ("Class A Shares"), class B subordinate voting shares ("Class B Shares"), and holders of warra

      11/21/23 8:45:00 AM ET
      $HUGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FSD Pharma Announces Distribution Date for Distribution of Celly Shares Pursuant to Plan of Arrangement

      TORONTO, ON / ACCESSWIRE / November 17, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that, further to its press release dated November 7, 2023, that its distribution date for the contemplated plan of arrangement (the "Arrangement") is November 29, 2023 (the "Distribution Date"). Subject to the satisfaction of all applicable closing conditions of the Arrangement, common shares in the capital of Celly Nutrition Corp. ("Celly Nu Shares") will be distributed to FSD Pharma Securityholders (as defined below) of record as of No

      11/17/23 8:00:00 AM ET
      $HUGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HUGE
    SEC Filings

    See more
    • SEC Form 6-K filed by FSD Pharma Inc.

      6-K - FSD Pharma Inc. (0001771885) (Filer)

      8/15/24 7:07:30 AM ET
      $HUGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 6-K/A filed by FSD Pharma Inc.

      6-K/A - FSD Pharma Inc. (0001771885) (Filer)

      8/14/24 6:15:16 AM ET
      $HUGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by FSD Pharma Inc.

      6-K - FSD Pharma Inc. (0001771885) (Filer)

      8/14/24 6:13:53 AM ET
      $HUGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HUGE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by FSD Pharma Inc. (Amendment)

      SC 13D/A - FSD Pharma Inc. (0001771885) (Subject)

      4/11/22 10:01:53 AM ET
      $HUGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by FSD Pharma Inc.

      SC 13D - FSD Pharma Inc. (0001771885) (Subject)

      3/31/21 9:52:01 PM ET
      $HUGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed

      SC 13D/A - FSD Pharma Inc. (0001771885) (Subject)

      2/22/21 11:35:38 AM ET
      $HUGE
      Biotechnology: Pharmaceutical Preparations
      Health Care